176 related articles for article (PubMed ID: 1906779)
1. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
4. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
5. [The role of interferons in neuroblastoma. 2: Immunomodulatory effects].
Handgretinger R; Bruchelt G; Daurer B; Lang P; Dopfer R; Reisfeld RA; Treuner J; Niethammer D
Klin Padiatr; 1990; 202(4):206-11. PubMed ID: 2118581
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
8. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
9. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
Hayakawa M
Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
[TBL] [Abstract][Full Text] [Related]
10. [Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma].
Tsunoda T; Tanimura H; Yamaue H; Tani M; Iwahashi M
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1110-8. PubMed ID: 2118938
[TBL] [Abstract][Full Text] [Related]
11. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.
Fady C; Gardner AM; Gera JF; Lichtenstein A
Cancer Res; 1992 Feb; 52(4):764-9. PubMed ID: 1346583
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma.
Tsunoda T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tamai M; Noguchi K; Arii K; Hotta T
Nihon Geka Hokan; 1991 Nov; 60(6):396-405. PubMed ID: 1820012
[TBL] [Abstract][Full Text] [Related]
13. Studies on the natural killer cell activity of human nonadherent mononuclear cells (nMNC) with tumor necrosis factor, interleukin-1, interferon-gamma and cisplatin.
Pai K; Sodhi A
Neoplasma; 1992; 39(6):363-7. PubMed ID: 1491726
[TBL] [Abstract][Full Text] [Related]
14. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein).
List J; Moser RP; Steuer M; Loudon WG; Blacklock JB; Grimm EA
Cancer Res; 1992 Mar; 52(5):1123-8. PubMed ID: 1737371
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
16. [Immunological study of interferon-gamma therapy for advanced renal cell carcinoma].
Aoyagi T; Murai M; Kimura F; Sawamura M; Asano T; Odajima K; Nagakura K; Nakamura H
Hinyokika Kiyo; 1992 Dec; 38(12):1357-60. PubMed ID: 1288223
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
18. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression.
Bogner MP; Voss SD; Bechhofer R; Hank JA; Roper M; Poplack D; Hammond D; Sondel PM
J Immunother (1991); 1992 Feb; 11(2):111-8. PubMed ID: 1571333
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
20. [A comparison of the suppressor and cytotoxic activities of the blood mononuclear cells during the adoptive immunotherapy of cancer patients using lymphokine-activated killers with a low dose of recombinant interleukin-2].
Abronina IF; Kupriianova TA; Bolvachova AV; Bykovskaia SN; Dronova OM; Buachidze LI
Biull Eksp Biol Med; 1991 Nov; 112(11):519-21. PubMed ID: 1839773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]